Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Roussel, Murielle; Lauwers‐Cancès, Valérie; Robillard, Nelly; Hulin, Cyrille; Leleu, Xavier; Benboubker, Lotfi; Marit, Gérald; Moreau, Philippe; Pégourie, Brigitte; Caillot, Denis; Fruchart, Christophe; Stoppa, Anne‐Marie; Gentil, Catherine; Wuillème, Soraya; Huynh, Anne; Hébraud, Benjamin; Corre, Jill; Chrétien, Marie‐Lorraine; Façon, Thierry; Avet-Loiseau, Hervé; Attal, Michel

doi:10.1200/jco.2013.54.8164

Cited by 246 publications

(270 citation statements)

References 24 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…1,2 The availability of many of these agents has led to several strategies in their use alone or in association either in the induction phase, the consolidation after auto-HSCT, the maintenance phase and the post-relapse phase or at the minimal-residual disease stage. 3,4,5,6,7,8 However, there is still a continuous risk of relapse mainly due to the inability of these agents to cure and eliminate definitively the MM cells. Allogeneic HSCT (allo-HSCT) remains a potentially curative treatment but its use is still controversial because of its high morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

et al. 2016

View full text Add to dashboard Cite

We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

show abstract

Section: Introductionmentioning

confidence: 99%

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, a recent trial by the Intergroupe Francophone du Myélome (IFM) combined the immunomodulatory drug lenalidomide with bortezomib/dexamethasone and demonstrated lower rates of grade II or over PN compared to already published results from prospective trials of bortezomib/doxorubicin combinations before autologous stem cell transplantation (ASCT). [8][9][10] No grade III or grade IV PN was observed in the IFM trial. 8 This underlines the impact of combination partners on bortezomib-induced toxicity and suggests that immunological effects might influence occurrence of PN.…”

mentioning

confidence: 99%

“…[8][9][10] No grade III or grade IV PN was observed in the IFM trial. 8 This underlines the impact of combination partners on bortezomib-induced toxicity and suggests that immunological effects might influence occurrence of PN.…”

mentioning

confidence: 99%

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

et al. 2016

View full text Add to dashboard Cite

“…Roussel et al 26 reported the use of two consolidation cycles of VRD following three VRD-induction cycles and ASCT. If after consolidation, CR rate increased only from 47 to 50%, sCR increased from 27 to 40%, highlighting the importance of consolidation to improve the depth of response.…”

Section: Consolidation Therapymentioning

confidence: 99%

Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

Mohty

Richardson

McCarthy

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Novel agents including proteasome inhibitors and immunomodulatory drugs are now routinely utilized as part of the induction regimen before transplantation and this has resulted in substantial improvements in the depth of response achieved before transplant. Given that depth of response is prognostic for overall outcome, a number of studies have been conducted or are ongoing to investigate the use of novel agents as consolidation and maintenance therapy after transplant. Most clinical trials have reported after consolidation and maintenance therapy an increased PFS and even overall survival in some of them. The use of postautologous stem cell transplant consolidation and maintenance is an increasingly attractive concept. However, some side effects could be observed with such long-term therapy and many open questions are still under debate. The decision to administer consolidation and/or maintenance therapy will likely need to be guided by the individual patient situation. This review aims to analyze the currently available research evidence in this field.

show abstract

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Cited by 246 publications

References 24 publications

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?

Contact Info

Product

Resources

About